MG-63 Transfection Kit (Osteosarcoma, CRL-1427)

$263.00$1,408.00

Kit Size VolumePriceAdd to Cart
0.5 ml (Catalog #6848)$263.00
1.5 ml (Catalog #6849)$536.00
1.5 ml CRISPR (Catalog #2173)$736.00
8.0 ml (Catalog #7063)$1,408.00
SKU: MG63 Category:

Description

Product Availability: In Stock (delivery within 2-3 business days, no extra charge for drop-shipping).

Ordering: To place an order via credit card or PO use Add to Cart button (creating an account is not required).


Transfection Reagent for MG-63 Cells (Osteosarcoma Cells, CRL-1427)

  • Two component formulation enhances lipid mediated transfection efficiency
  • Optimized easy-to-use transfection protocol provided for transfection of siRNA, DNA, mRNA, and microRNA
  • High transfection efficacy in the presence of serum
  • Expand your RNAi application with a reagent optimized for delivery of both siRNA and plasmid
  • Reproducible transfection results
  • Works well for standard reverse transfection and high-throughput applications
  • Download in vitro MG63 transfection protocol: [PDF]
  • Download MG63 CRISPR/Cas9 transfection protocol: [PDF]
  • Download PowerPoint presentation for NIH3T3 transfection kit: [PPT]
  • UPC/GTIN/EAN: 860002089789
  • Brand: ALTOGEN®, developed and manufactured by Altogen Biosystems

Transfection Efficiency:

Reagent exhibits at least 77% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.

Transfection Protocol and MSDS:

Download Altogen Biosystems MG-63 Transfection Protocol: [PDF]

Download MSDS: [PDF]

MG-63 Cell Line:

Sarcoma is a cancer of bones and connective tissues that is quite rare in adults. However, it comprises approximately 20% of all childhood cancers, as indicated by the Sarcoma Foundation of America (SFA). Human cell lines are valuable preclinical models for sarcoma research as well as for evaluation of the efficacy or toxicity of potential drug candidates. The MG-63 cell line was established from the bone tissue of a 14-year-old Caucasian male with osteosarcoma. This cell line exhibits fibroblast morphology and shows high levels of interferon production when induced by cycloheximide, actinomycin D, and polyinosinic-polycytidylic acid. These MG-63 cells express TGF-beta RI and TGF-beta RII receptors and could be useful as a transfection host in different types of biomedical research applications. The MG-63 cell line is hypotriploid with a modal chromosome number of 66. Altogen Biosystems provides high-efficiency transfection reagent kits for the MG-63 osteosarcoma cell line.

Mutations:

NPHP3 27031 37 3 132440868 132440868 Missense_Mutation SNP G C
CAPS2 84698 37 12 75687068 75687068 Missense_Mutation SNP C T
RHBDF2 79651 37 17 74475004 74475004 Missense_Mutation SNP C T
NLRP12 91662 37 19 54313326 54313326 Missense_Mutation SNP G C
NOC2L 26155 37 1 891321 891321 Missense_Mutation SNP A C
ATAD3C 219293 37 1 1387769 1387769 Silent SNP A G
PADI1 29943 37 1 17556646 17556646 Silent SNP C G
HSPG2 3339 37 1 22176941 22176941 Silent SNP G A
STPG1 90529 37 1 24727851 24727851 Missense_Mutation SNP G T
HMGB4 127540 37 1 34329841 34329841 Missense_Mutation SNP G A

Data:

MG63 Transfection Reagent

Figure 1. siRNAs targeting Lamin A/C mRNA or non-silencing control siRNA were transfected into MG63 cells following the recommended protocol. At 48 hours post-transfection the cells were analyzed by qRT-PCR for Lamin A/C gene expression levels. 18S rRNA levels were used to normalize the Lamin A/C data. Values are normalized to untreated sample. Data are means ± SD (n=4).

MG63-cells-transfection-protocol

Figure 2. Protein expression of Lamin A in MG-63 cells. DNA plasmid expressing Lamin A or siRNA targeting Lamin A were transfected into MG-63 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.

MG63 Transfection Reagent citation references:

  • Data Brief. 2016 Jun; 7: 177–182. Data supporting attempted caveolae-mediated phagocytosis of surface-fixed micro-pillars by human osteoblasts. Moerke et al [PDF]

 

Altogen Biosystems:
Altogen Biosystems provides pre-optimized transfection kits and electroporation products for life science research. Transfection products are developed for individual cancer cell line and transfection protocols are optimized to enable high transfection  efficiency of biomolecules. Altogen Biosystems developed in vivo delivery products for small animal research, mouse and rat targeted tissue delivery: liver targeted, pancreas targeted, kidney targeted, PEG-Liposome-, Nanoparticle-, Lipid-, and Polymer-based in vivo transfection kits. Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of biomolecules. Read more about transfection technology at Altogen’s Transfection Resource.

Altogen Labs Research Services:

Altogen Labs provides GLP compliant contract research studies for preclinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (90+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).

Volume Options:

  • 0.5 ml (Catalog #6848)
  • 1.5 ml (Catalog #6849)
  • 1.5 ml CRISPR (Catalog #2173)
  • 8.0 ml (Catalog #7063)

Additional information

Weight 1 lbs
Kit Size (Volume)

0.5 ml (Catalog #6848), 1.5 ml (Catalog #6849), 1.5 ml CRISPR (Catalog #2173), 8.0 ml (Catalog #7063)